Troy Wichterman Sells 932 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 932 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $20.11, for a total transaction of $18,742.52. Following the completion of the transaction, the chief financial officer now owns 188,310 shares of the company’s stock, valued at approximately $3,786,914.10. This trade represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, April 1st, Troy Wichterman sold 25,687 shares of BioLife Solutions stock. The stock was sold at an average price of $22.66, for a total transaction of $582,067.42.
• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.

BioLife Solutions Stock Up 4.3 %

BioLife Solutions stock opened at $21.90 on Monday. The company has a market capitalization of $1.03 billion, a PE ratio of -20.66 and a beta of 1.93. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The firm’s fifty day moving average is $25.04 and its 200 day moving average is $25.35. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the business earned ($0.21) earnings per share. As a group, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. grew its stake in BioLife Solutions by 1.1% in the fourth quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock valued at $84,097,000 after acquiring an additional 36,176 shares during the period. Fred Alger Management LLC grew its position in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock valued at $41,386,000 after purchasing an additional 16,274 shares during the period. State Street Corp increased its stake in BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Millennium Management LLC increased its stake in BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after purchasing an additional 377,111 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in BioLife Solutions by 4.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after buying an additional 40,416 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. StockNews.com upgraded BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, April 8th. HC Wainwright upped their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, Northland Securities boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.